FDA Social Media Review From Dose Of Digital

by Jonathan Richman on Nov 19, 2009

4,397 views

A handful of new information came out at the FDA pharma social media hearings, but quite a bit was missing as well. Here's my brief overview of what I learned and what I thought was missing

More…

A handful of new information came out at the FDA pharma social media hearings, but quite a bit was missing as well. Here's my brief overview of what I learned and what I thought was missing

Less

3 Embeds 960

http://www.doseofdigital.com	951
http://www.slideshare.net	7
https://www.facebook.com	2

Statistics

Favorites: 8
Downloads: 74
Comments: 3
Embed Views: 960
Views on SlideShare: 3,437
Total Views: 4,397

FDA Social Media Review From Dose Of Digital — Webinar Transcript

Three Things I Learned at the FDA Hearings and Three I Wish I Had Jonathan Richman Director of Strategic Planning, Bridge Worldwide Author, Dose of Digital @jonmrich

Yes, I was there...

...along with 60+ of my close friends

Two themes What I learned What I didn’t (but wish I had)

What I learned

The FDA gets it

MedWatch is dead

Consumers might actually want us there

(a serious AE, BTW)

What I didn’t

FDA’s plan for keeping up

The end of red herrings

What pharma REALLY wants to do

What I learned

The FDA gets it

MedWatch is dead

Consumers might actually want us there

The FDA gets it

“ Since the 1996 public meeting, there has been a massive expansion of new tools and technologies, such as blogs, microblogs, podcasts, social network sites (‘social networks’) and online communities, video sharing, widgets, and wikis...”

The FDA gets it

For what online communications is pharma accountable?

How can pharma follow the rules in using tools with space limitations and real-time comms?

What rules apply to the posting of corrective info on websites controlled by third parties?

When is the use of links appropriate?

Questions specific to Internet adverse event reporting

MedWatch is dead

MedWatch is dead Courtesy of Ignite Health

MedWatch is dead

Consumers might actually want us there

AGREE that healthcare companies’ use of social media...

...provides important updates on products and services – 79%

...brings accurate information into conversations about drugs or devices – 73%

...addresses frequently asked questions about products and services – 66%

...adds valuable professional expertise to the conversation – 62%

Good News

Consumers might actually want us there If I double the dose, would the blisters go away faster? Double your dose and see what happens, but I wouldn’t hold my breath.

Consumers might actually want us there

AGREE healthcare companies...

...should monitor and correct misperceptions or misinformation when that info can be harmful – 90%

...should be responsible for policing any unauthorized versions of their content – 64%

Bad News

Consumers might actually want us there

In short...

To whom much is given, much is expected.

What I didn’t

FDA’s plan for keeping up

The end of the red herrings

What pharma REALLY wants to do

FDA’s plan for keeping up

FDA’s plan for keeping up 1996 2022 2009 FDA Technology-Related Hearings Schedule

The end of red herrings Only 1 in 500 posts qualifies as a “reportable adverse event”

The end of red herrings Source: Nielsen BuzzMetrics, Personal Communications Nielsen BuzzMetrics total Healthcare discussions (~1,350 sites): 82,697 per day Percentage of posts with a reportable adverse event: 0.2% Number of reportable adverse events for the ENTIRE INDUSTRY : 166 per day

The end of red herrings

Adverse event reporting

Off label discussions

Personal identifying information

Monitoring volume and resources

FTC regulations

Technology integration

No clear precedents

Lack of internal expertise

The end of red herrings

What pharma REALLY wants to do ?

What pharma really wants to do ?

What pharma really wants to do

For what online communications is pharma accountable?

How can pharma follow the rules in using tools with space limitations and real-time comms?

What rules apply to the posting of corrective info on websites controlled by third parties?

When is the use of links appropriate?

Questions specific to Internet adverse event reporting

What pharma really wants to do

Does allowing additional leeway for pharma to participate in social media improve or harm public health?

Three Things I Learned at the FDA Hearings and Three I Wish I Had

Contact Me

Text Healthcare to 50500

Jonathan Richman

513.253.1295

[email_address]

Twitter: @jonmrich

This presentation: http://bit.ly/ dodfda

http://www.doseofdigital.com

http://www.bridgeworldwide.com

Contact Me

Greg Matthews , Group Director, Interactive and Social Media at WCG You're right, JMR! Enjoying the whole enchilada now. 1 year ago

Are you sure you want to Yes No

Jonathan Richman , VP, Product Marketing at Zipscene at Jonathan Richman If you view in slideshare, you should see it as a SlideCast meaning that if you press the play button, you'll get my audio synced to the slides. 1 year ago

Greg Matthews , Group Director, Interactive and Social Media at WCG Nice overview from @jonmrich ... only wish I had the talk-track that went with these great images! 1 year ago

FDA Social Media Review From Dose Of Digital

by Jonathan Richman on Nov 19, 2009

Accessibility

Categories

Tags

Upload Details

Usage Rights

3 Embeds 960

Statistics

FDA Social Media Review From Dose Of Digital — Webinar Transcript